Physiological changes associated with the metabolic syndrome may play a role in the risk of postmenopausal breast cancer, according to study results published in Cancer Epidemiology, Biomarkers 's38; Prevention, a journal of the American Association for Cancer Research (www.aacr.org).
The metabolic syndrome, or insulin resistance syndrome, consists of a constellation of factors including abdominal obesity, high blood glucose levels, impaired glucose tolerance, abnormal
lipid levels and high blood pressure.
Affecting roughly 47 million Americans, the metabolic syndrome is also associated with poor diet and lack of physical activity. It can also increase the risk for diabetes and heart
disease.
The metabolic syndrome is characterized by elevated insulin levels, and in recent years scientists have proposed that insulin may contribute directly or indirectly to the development of
breast cancer. Researchers suspect that the metabolic syndrome could influence the risk for breast cancer by affecting interrelated hormones, such as insulin, estrogen, cytokines and
growth factors.
's8220;This study suggests that having the metabolic syndrome itself or some of its components may increase a woman's8217;s risk of postmenopausal breast cancer. However, much more work
is needed to understand the role of these metabolic factors and their interplay with better established breast cancer risk factors, such as reproductive and hormonal factors,'s8221; said
researcher Geoffrey C. Kabat, Ph.D., senior epidemiologist in the department of epidemiology and population health at Albert Einstein College of Medicine, New York.
Studies to date have evaluated individual components of the metabolic syndrome and breast cancer, with inconsistent results, according to Kabat. For the first time, Kabat and colleagues
assessed whether women who met the criteria of having the metabolic syndrome were at greater risk for postmenopausal breast cancer.
In this longitudinal study, the researchers used existing data from the Women's8217;s Health Initiative 's8212; a large, national study designed to assess major causes of chronic disease
in women. Participants included postmenopausal women aged 50 to 79 years at enrollment who had repeated measurements of components of metabolic syndrome over an eight-year period. These
included blood levels of glucose, HDL-cholesterol and triglycerides, as well as waist girth and blood pressure.
Results showed a modest positive association of having the metabolic syndrome as a whole, according to Kabat. Of the 4,888 women with baseline measurements who did not have diabetes, 165
incident cases of breast cancer were diagnosed during the follow-up period. Presence of the metabolic syndrome at baseline was not associated with breast cancer risk.
However, in analyses that made use of the repeated measurements, 's8220;women who had the metabolic syndrome during the three to five years prior to breast cancer diagnosis had roughly a
doubling of risk,'s8221; he said.
Findings also showed significant associations with elevated blood glucose levels, triglycerides and diastolic blood pressure. For diastolic blood pressure, the result was stronger, with
more than a two-fold increased risk (relative risk = 2.4). Generally, for both triglycerides and glucose the relative risk was about 1.7 for all breast cancer.
's8220;We know a great deal about breast cancer, but we can's8217;t identify who is likely to get it. The effect of different variables associated with increased glucose and insulin
levels needs to be evaluated further in larger studies,'s8221; Kabat said. 's8220;We need to deepen our understanding of these different interrelated behaviors and physiological factors
to see how they affect breast cancer.'s8221;
Tim Byers, M.D., M.P.H., associate dean of the Colorado School of Public Health and interim director of the University of Colorado Cancer Center, believes these findings are important
because the results show possible mechanisms that might explain the observation that increased weight is a risk factor for postmenopausal breast cancer.
's8220;We have assumed that the relationship between weight and breast cancer risk is due to increased circulating estrogens among postmenopausal women who are overweight or obese,'s8221;
he said. 's8220;An alternative explanation is explored here: that some other aspect of the metabolic syndrome might be involved, such as growth-stimulating effects of insulin, or
insulin-like growth factors.'s8221;
Based on the results of this study, Byers stated that researchers now need to look more closely at dynamic changes in insulin over time, in factors tied to inflammation, and in the
specific ways in which estrogen metabolism is tied to features of the metabolic syndrome.
's8220;Though estrogens are produced in adipose tissues, just how these are metabolized in various subgroups of women needs better study,'s8221; he said. 's8220;In addition, the
hyper-inflammatory state of obesity and the metabolic syndrome need to be better described relative to cancer risk.'s8221;
Additional Resources:
Subscribe to the Cancer Epidemiology, Biomarkers and Prevention RSS feed (http://cebp.aacrjournals.org/rss/recent.xml)
Learn More about diet and breast cancer through an article (http://www.crmagazine.org/archive/Breastcancer2008/Pages/TheSimpleLife.aspx) from CR Magazine, the
AACR'ss publication for patients, survivors and scientists.
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's8217;s oldest and largest professional organization
dedicated to advancing cancer research. The membership includes more than 28,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and
advocates in the United States and nearly 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention,
diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than
17,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer
research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer
Research; Cancer Epidemiology, Biomarkers 's38; Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient
advocates, physicians and scientists. CR provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.